Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.43 |
| ▸ | MEN1 | O00255 | 6/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | HTT | P42858 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LOX | P28300 | 1/20 | 0.40 |
| ▸ | HK1 | P19367 | 1/20 | 0.39 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1772255 | 0.81 | CYP3A4 (0.42) | CA12CA2CA9SMN1; SMN2 | |
| SCHEMBL6313736 | 0.81 | CA2 (0.40) | CA12CA2CA9 | |
| SCHEMBL483895 | 0.80 | LMNA (0.45) | RAB9ANPC1KMT2AMEN1CA12 | |
| SCHEMBL7163455 | 0.78 | RAB9A (0.63) | RAB9ANPC1TNFNOD1KMT2A | |
| SCHEMBL241807 | 0.77 | CA2 (0.60) | CA12CA2CA9 | |
| SCHEMBL11298641 | 0.77 | SENP3 (0.52) | KMT2AMEN1CA12CA2CA9 | |
| SCHEMBL11296127 | 0.77 | TDP1 (0.44) | CA12CA2CA9ALDH1A1 | |
| SCHEMBL11291209 | 0.77 | CYP3A4 (0.39) | KMT2AMEN1CA12CA2CA9 | |
| SCHEMBL183418 | 0.76 | CA2 (0.39) | CA12CA2CA9 | |
| Hydrochloric Acid SCHEMBL11296130 | 0.76 | SENP3 (0.51) | KMT2AMEN1CA12CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905288-B1 | Pyrido[3″,4″:4′, 5′]pyrrolo[3′,2′:4,5]imidazole[1,2-c]pyrimidine compounds as CK2 inhibitors | King Faisal University (SA) | 2024-02-20 | — | — | US | disclosed |
| US-11891396-B1 | 5-substituted pyrido[3″,4″:4′,5′]pyrrolo[3′,2′:4,5]imidazo[1,2-a]pyrazine compounds as CK2 inhibitors | King Faisal University (SA) | 2024-02-06 | — | — | US | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891396-B1 | 5-substituted pyrido[3″,4″:4′,5′]pyrrolo[3′,2′:4,5]imidazo[1,2-a]pyrazine compounds as CK2 inhibitors | CSNK2A1, CSNK2A2, CSNK2A3 | RAB9A 4180/4885NPC1 4108/4885TNF 946/4885 |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | RAB9A 2980/4885NPC1 1959/4885TNF 2941/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | RAB9A 2980/4885NPC1 1959/4885TNF 2941/4885 |
| US-11905288-B1 | Pyrido[3″,4″:4′, 5′]pyrrolo[3′,2′:4,5]imidazole[1,2-c]pyrimidine compounds as CK2 inhibitors | CDK2, CKS2, CDK4 | RAB9A 4012/4885NPC1 3987/4885TNF 665/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | RAB9A 2980/4885NPC1 1959/4885TNF 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.